Sector Overview
The Healthcare sector has seen steady filing activity over the past 12 months, with companies across the industry reporting on evolving market conditions and strategic initiatives. Annual 10-K filings from the sector's largest companies reveal a mix of operational improvements and forward-looking investments aimed at maintaining competitive positioning.
Quarterly 10-Q filings have highlighted ongoing adjustments to macroeconomic conditions, including interest rate sensitivity and supply chain dynamics. Several companies have disclosed material changes in their risk factors, reflecting the sector's adaptation to regulatory developments and shifting demand patterns.
Key Themes
- Companies adjusting strategies in response to macroeconomic conditions
- Increased disclosure around risk factors and regulatory compliance
- Capital allocation shifting toward long-term strategic investments
- Operational efficiency initiatives featuring in management discussions
Updated Jan 2025 · Based on filings from top Healthcare companies
Company Rankings
| # | Ticker | Company | Industry | Market Cap * | Filings |
|---|---|---|---|---|---|
| 1 | ABBV | AbbVie Inc. | Pharmaceutical Preparations | - | 242 |
| 2 | ABT | ABBOTT LABORATORIES | Pharmaceutical Preparations | - | 425 |
| 3 | AFL | AFLAC INC | Accident & Health Insurance | - | 372 |
| 4 | AMGN | AMGEN INC | Biological Products, (No Diagnostic Substances) | - | 452 |
| 5 | BDX | BECTON DICKINSON & CO | Surgical & Medical Instruments & Apparatus | - | 547 |
| 6 | BMY | BRISTOL MYERS SQUIBB CO | Pharmaceutical Preparations | - | 526 |
| 7 | BSX | BOSTON SCIENTIFIC CORP | Surgical & Medical Instruments & Apparatus | - | 547 |
| 8 | CAH | CARDINAL HEALTH INC | Wholesale-Drugs, Proprietaries & Druggists' Sundries | - | 499 |
| 9 | CI | Cigna Group | Hospital & Medical Service Plans | - | 156 |
| 10 | COR | Cencora, Inc. | Wholesale-Drugs, Proprietaries & Druggists' Sundries | - | 542 |
| 11 | CVS | CVS HEALTH Corp | Retail-Drug Stores and Proprietary Stores | - | 517 |
| 12 | ELV | Elevance Health, Inc. | Hospital & Medical Service Plans | - | 480 |
| 13 | GILD | GILEAD SCIENCES, INC. | Biological Products, (No Diagnostic Substances) | - | 431 |
| 14 | HCA | HCA Healthcare, Inc. | Services-General Medical & Surgical Hospitals, NEC | - | 535 |
| 15 | JNJ | JOHNSON & JOHNSON | Pharmaceutical Preparations | - | 456 |
| 16 | LLY | ELI LILLY & Co | Pharmaceutical Preparations | - | 368 |
| 17 | MCK | MCKESSON CORP | Wholesale-Drugs, Proprietaries & Druggists' Sundries | - | 462 |
| 18 | MDT | Medtronic plc | Electromedical & Electrotherapeutic Apparatus | - | 177 |
| 19 | MMM | 3M CO | Surgical & Medical Instruments & Apparatus | - | 550 |
| 20 | MRK | Merck & Co., Inc. | Pharmaceutical Preparations | - | 413 |
| 21 | PFE | PFIZER INC | Pharmaceutical Preparations | - | 481 |
| 22 | REGN | REGENERON PHARMACEUTICALS, INC. | Pharmaceutical Preparations | - | 421 |
| 23 | SYK | STRYKER CORP | Surgical & Medical Instruments & Apparatus | - | 390 |
| 24 | UNH | UNITEDHEALTH GROUP INC | Hospital & Medical Service Plans | - | 580 |
| 25 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Pharmaceutical Preparations | - | 411 |
Showing 1–25 of 26
Trending 8-K Filings
Cencora, Inc. 8-K Report, Regulation FD Disclosure (Feb 18, 2026)
Cencora, Inc. (COR) has announced a significant strategic transaction involving its animal health business, MWI Animal Health. The company has entered into a definitive agreement to merge MWI with Covetrus, Inc. This transaction, which values MWI at an enterprise value of $3.5 billion, represents a pivotal step in reshaping Cencora's business focus and aims to unlock value for shareholders. The deal structure includes substantial upfront cash and equity in the combined entity, positioning Cencora for potential future upside while divesting a key segment. The merger is expected to provide Cencora with $1.25 billion in upfront cash and significant equity ownership (approximately 34.3%) in the indirect parent of Covetrus, CVET TopCo, LP, through preferred and common units valued at $2.25 billion. This cash infusion will likely bolster Cencora's financial flexibility, while the equity stake offers participation in the growth of the combined animal health business. The transaction is subject to customary closing conditions, including regulatory approvals, and is anticipated to be a key event for Cencora's strategic direction and financial profile.
Medtronic plc 8-K Report, Financial Results (Feb 17, 2026)
Medtronic plc (MDT) has filed an 8-K report on February 17, 2026, to announce its third quarter fiscal year 2026 financial results. The primary purpose of this filing is to furnish the press release detailing these results, which were released on the same day. Investors should review the press release (Exhibit 99.1) for specific performance metrics, revenue figures, profitability, and any forward-looking statements or guidance provided by the company for the remainder of the fiscal year. This report serves as the official notification of the company's recent financial performance. While the 8-K itself is brief, it directs investors to the comprehensive financial data contained within the furnished press release. Key areas of interest for investors will likely include the performance of Medtronic's various business segments, comparisons to analyst expectations, and any commentary on the macroeconomic or industry-specific factors impacting the results. Understanding these details is crucial for assessing Medtronic's current financial health and future prospects.
Cencora, Inc. 8-K Report, Material Agreement (Feb 13, 2026)
Cencora, Inc. (COR) has filed an 8-K report detailing the successful closing of a $3.0 billion aggregate principal amount senior notes offering on February 13, 2026. This offering comprises multiple tranches with varying interest rates and maturity dates, ranging from 3.950% notes due 2029 to 5.650% notes due 2056. The proceeds from this significant debt issuance will be used for general corporate purposes, though specific use cases are not detailed in this filing. The issuance represents a substantial capital raise for Cencora, impacting its debt structure and financial leverage. Investors should note that these notes are unsecured and unsubordinated, ranking equally with existing unsecured and unsubordinated debt, but are structurally subordinated to all debt and liabilities of the company's subsidiaries. The indentures governing these notes include covenants related to liens, sale and leaseback transactions, and mergers, alongside standard events of default. This filing provides detailed information on the terms, interest rates, maturity dates, and redemption provisions for each series of notes.
Zoetis Inc. 8-K Report, Financial Results (Feb 12, 2026)
Zoetis Inc. (ZTS) has filed an 8-K report on February 12, 2026, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2025. The filing also includes the company's financial guidance for the upcoming full year 2026. Investors should refer to the furnished press release (Exhibit 99.1) for detailed financial performance metrics and future outlook. While specific figures are not detailed within the 8-K text itself, the furnished press release is the key document for understanding Zoetis' performance in 2025, including revenue, profitability, and key growth drivers. Furthermore, the guidance provided for 2026 will be crucial for assessing the company's strategic direction and potential for continued growth in the animal health sector.
VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Feb 12, 2026)
Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K report on February 12, 2026, announcing its consolidated financial results for the fourth quarter and full fiscal year ended December 31, 2025. While the specific financial figures are detailed in the press release (Exhibit 99.1), this filing serves as the official notification to the market of these results. Investors should refer to the press release for critical performance indicators, revenue streams, profitability, and any forward-looking statements or guidance provided by the company.
Cencora, Inc. 8-K Report, Regulation FD Disclosure (Feb 11, 2026)
Cencora, Inc. (COR) has announced the pricing of a significant senior notes offering totaling $2.5 billion across multiple tranches with varying maturity dates and coupon rates. These notes include $500 million in 3.950% Senior Notes due 2029, $500 million in 4.250% Senior Notes due 2030, $500 million in 4.600% Senior Notes due 2033, $1 billion in 4.900% Senior Notes due 2036, and $500 million in 5.650% Senior Notes due 2056. The company expects to receive approximately $2.98 billion in net proceeds from this offering, after deducting underwriting discounts and expenses.
Cencora, Inc. 8-K Report, Corporate Update (Feb 10, 2026)
Cencora, Inc. (COR) has filed an 8-K to revise the presentation of its financial information within its previously filed 2025 Form 10-K. This revision is a result of a strategic review that led to a reorganization of its reporting structure, effective from the first quarter of fiscal year 2026. The company has moved to a new reporting structure consisting of three components: U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions segment now includes U.S. Human Health (excluding legacy U.S. Consulting Services), while International Healthcare Solutions encompasses Alliance Healthcare, Innomar, World Courier, and specific components of Pharmalex. The 'Other' category, not considered a reportable segment, includes businesses for which strategic alternatives are being explored, such as MWI Animal Health, Profarma, U.S. Consulting Services, and remaining Pharmalex components. This filing updates specific sections of the 2025 Form 10-K to reflect this new segment alignment, though it does not amend or restate the audited consolidated financial statements themselves.
GILEAD SCIENCES, INC. 8-K Report, Financial Results (Feb 10, 2026)
Gilead Sciences, Inc. (GILD) has filed an 8-K report on February 10, 2026, announcing its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily serves to disseminate this earnings information to investors. Investors should refer to Exhibit 99.1, the press release, for detailed financial performance, including both GAAP and non-GAAP measures. Management emphasizes that while non-GAAP information is provided for enhanced operational and financial planning insights, it is not a substitute for GAAP figures. A reconciliation of these non-GAAP measures to their GAAP equivalents is available within the press release. The filing itself is procedural, directing stakeholders to the comprehensive earnings announcement for substantive financial details and commentary.
CVS HEALTH Corp 8-K Report, Financial Results (Feb 10, 2026)
CVS Health Corporation filed an 8-K on February 10, 2026, to furnish a press release announcing its financial results for the three months and full year ended December 31, 2025. While the filing itself does not contain detailed financial figures, it directs investors to the press release (Exhibit 99.1) for this crucial information. The press release, therefore, is the primary source for understanding the company's recent performance and financial condition. Investors should carefully review the furnished press release to gain insights into key performance indicators, revenue growth, profitability, and any forward-looking statements or guidance provided by CVS Health. The 8-K filing serves as a formal notification and makes the press release publicly available, ensuring transparency regarding the company's financial reporting for the period ending December 31, 2025.
BECTON DICKINSON & CO 8-K Report, Corporate Update (Feb 10, 2026)
Becton, Dickinson and Company (BDX) has announced the commencement of a significant tender offer program, seeking to repurchase up to $1.6 billion in aggregate principal amount of its outstanding senior notes and debentures. This action indicates a strategic move by the company to manage its debt obligations and potentially optimize its capital structure. Investors should note the broad range of maturities and coupon rates for the notes being tendered, suggesting a comprehensive approach to debt refinancing or deleveraging. The company's willingness to offer cash for these debt instruments, up to a substantial aggregate amount, may signal confidence in its current liquidity position and future cash flow generation. This tender offer is a key event for bondholders and could influence the company's future financing costs and overall financial flexibility.
Frequently Asked Questions
Updated Jan 2025 · Based on SEC filings from Healthcare companies